Ophthotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Ophthotech and buy or sell other stocks, ETFs, and their options commission-free!

About OPHT

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. 

CEO
Glenn P. Sblendorio, MBA
CEOGlenn P. Sblendorio, MBA
Employees
Employees
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
2007
Founded2007
Employees
Employees

OPHT Key Statistics

Market cap
5.51B
Market cap5.51B
Price-Earnings ratio
-22.69
Price-Earnings ratio-22.69
Dividend yield
Dividend yield
Average volume
6.52M
Average volume6.52M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$39.99
52 Week high$39.99
52 Week low
$9.39
52 Week low$9.39

Stock Snapshot

The current Ophthotech(OPHT) stock price is $5.60, with a market capitalization of 5.51B. The stock trades at a price-to-earnings (P/E) ratio of -22.69.

Ophthotech(OPHT) stock opened on 2026-03-17 at —. The price climbed to — and dipped to —.

Ophthotech(OPHT) shares are trading with a volume of 0, against a daily average of 6.52M.

In the last year, Ophthotech(OPHT) shares hit a 52-week high of $39.99 and a 52-week low of $9.39.

In the last year, Ophthotech(OPHT) shares hit a 52-week high of $39.99 and a 52-week low of $9.39.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.